Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA
What they do
Kintsugi develops a voice biomarker API that analyzes brief speech patterns in patient conversations to flag signs of clinical depression and anxiety. This tool integrates into telehealth sessions and clinical intake processes to aid mental health practitioners.
The record
- Vertical
- Clinical AI
- Sub-segment
- Voice biomarker diagnostics
- Product type
- Software as a medical device
- Stage
- Series A
- Headquarters
- Berkeley, United States
- Region
- North America
- Founded
- 2019
- Total funding
- $28M raised
Notable investors: General Catalyst, Windham Venture Partners, Acrew Capital, Candid Group.
Also in Clinical AI
Related on The Signal
Dr. Dereck Mush, MD, MBA
Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
The Physical AI Shift in Post-Acute Care: Inside Inspiren's $500M+ Bet
Dr. Dereck Mush, MD, MBA
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
Dr. Dereck Mush, MD, MBA